The role of inflammatory agents in endothelial function and their contribution to atherosclerosis

Hellenic Journal of Cardiology

Volumn 46, Issue 3, 2005, Pages 232-239

  Karatzis, Emmanouil N ^a,b  

^a RED CROSS HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

Atherosclerosis; Endothelial function; Inflammatory agents

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ARGININE; ASCORBIC ACID; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; FLAVONOID; FOLIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; LIPOPOLYSACCHARIDE; NITRIC OXIDE; OXYGEN RADICAL; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; BIOLOGICAL MARKER;

ATHEROSCLEROSIS; CELL ADHESION; CELL MIGRATION; ENDOTHELIUM; EXERCISE; HUMAN; INFECTION; INFLAMMATION; LEUKOCYTE; REVIEW; SHEAR STRESS; ARTERIOSCLEROSIS; CELL PROLIFERATION; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CELL ADHESION; CELL PROLIFERATION; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION MEDIATORS; MUSCLE, SMOOTH, VASCULAR; OXIDATIVE STRESS; RISK FACTORS; VASOCONSTRICTION;

EID: 24644517686     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Vallance P, Webb D: Vascular endothelium in human physiology and pathophysiology. Harwood Academic Publishers, Amsterdam, The Netherlands, 2000.
2. Blake G, Ridker P: Novel clinical markers of vascular wall inflammation. Circ Res 2001; 89: 763-771.
3. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
4. Monaco C, Andreakos E, Kiriakidis S, et al: Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci USA 2004; 101: 5634-5639.
5. Libby P, Ross R: Cytokines and growth regulatory molecules in atherosclerosis, in Fuster V, Ross R and Topol EJ (eds): Atherosclerosis and coronary artery disease. Lippincott Raven, Philadelphia, 1996; pp 585-592.
6. Ridker PM, et al: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-1772.
7. Schmid-Schonbein GW, Neil Granger D: Molecular basis for microcirculatory disorders. Springer-Verlag, Paris, France, 2003.
8. Arfors KE, Lundberg C, Lindbom L, Lundberg K, Beatty PG, Harlan JM: A monoclonal antibody to the membrane glycoprotein complex CD 18 inhibits polymorphonuclear leukocyte accumulation and plasma leakage in vivo. Blood 1987; 69: 338-340.
9. Newton-Nash DK, Newman PJ: A new role for platelet-en-dothelial cell adhesion molecule-1 (CD31): Inhibition of TCR-mediated signal transduction. J Immunol 1999; 63: 682-688.
10. Lipowsky HH, House SD, Firrell JC: Leukocyte endothelium adhesion and microvascular hemodynamics. Adv Exp Med Biol 1988; 242: 85-93.
11. Ley K: Leukocyte recruitment as seen by intravital microscopy, in Ley K (ed): Physiology of Inflammation. Oxford University Press, New York, 2001.
12. Fleming JC, Berger G, Guichard J, Cramer EM, Wagner DD: The transmembrane domain enhances granular targeting of P-selectin. European J Cell Biol 1998; 75: 331-343.
13. Ley K, Allietta M, Bullard DC, Morgan SJ: Importance of E-selectin for firm leukocyte adhesion in vivo. Circ Res 1998; 83: 287-294.
14. Kuijpers TW, Tool ATJ, van der School CE, et al: Membrane surface antigen expression on neutrophils: A reappraisal of the use of surface markers for neutrophil activation. Blood 1991; 78: 1105-1111.
15. Moy VT, Florin EL, Gaub HE: Intermolecular forces and energies between ligands and receptors. Science 1994; 266: 257-259.
16. Huang AJ, Manning JE, Bandak TM, Ratau MC, Hanser KR, Silverstein SC: Endothelial cell cytosolic free calcium regulates neutrophil migration across monolayers of endothelial cells. J Cell Biol 1993; 120: 1371-1380.
17. Cirino G, Fiorucci S, Sessa W: Endothelial nitric oxide synthase: The Cinderella of inflammation? Trends Pharmacol Sci 2003; 24: 91-95.
18. Lusis A: Atherosclerosis. Nature 2000; 407: 233-241.
19. De Bakey ME, Lawrie GM, Glaeser DH: Patterns of atherosclerosis and their surgical significance. Ann Surg 1985; 201: 115-131.
20. Rubanyi GM, Romero JC, Vanhoutte PM: Flow induced release of endothelium derived relaxing factor. Am J Physiol 1986; 250: H1145-1149.
21. Traub O, Berk BC: Laminar shear stress: Mechanisms by which endothelial cells transduce an atheroprotective force. Arterioscler Thromb Vasc Biol 1998; 18: 677-685.
22. Arnal JF, Dinh-Xuan AT, Pueyo M, Darblade B, Rami J : Endothelium-derived nitric oxide and vascular physiology and pathology. Cell Mol Life Sci 1999; 55: 1078-1087.
23. Moroi M, Zhang L, Yasuda T, et al: Interaction of genetic deficiency of endothelial nitric oxide, gender and pregnancy in vascular response to injury in mice. J Clin Invest 1998; 101: 1225-1232.
24. Frangos JA, Eskin SG, McIntere LY, Ives CL: Flow effects on prostacyclin production by cultured human endothelial cells. Science 1985; 227: 1477-1479.
25. Tedgui A, Mallat Z: Anti-inflammatory mechanisms in the vascular wall. Circ Res. 2001; 88: 877-887.
26. Rosen GM, Freeman BA: Detection of Superoxide generated by endothelial cells. Proc Natl Acad Sci USA 1984; 81: 7269-7273.
27. Dayoub H, Achan V, Adimmoolam S, et al: Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 2003; 108: 3042-3047.
28. Boger RH, Bode-Boger SM, Szuba A, et al: Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation 1998; 98: 1842-1847.
29. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.
30. Galle J, Quaschning T, Seibold S, Wanner C: Endothelial dysfunction and inflammation. What is the link? Kidney Int Suppl 2003; 84: S45-49.
31. Karatzis E, Lekakis J, Papamichael C, et al: Rapid effect of pravastatin on endothelial function and lipid peroxidation in unstable angina. Int J Cardiol 2005; 101: 65-70.
32. Pugin J, Ulevitch RJ, Tobias PS: A critical role for monocytes and CD 14 in endotoxin-induced endothelial cell activation. J Exp Med 1993; 178: 2193-2200.
33. Hingorrani AD, Cross J, Kharbanda RK, et al: Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000; 102: 994-999.
34. Ridker PM, Henneskens CH, Stampher MJ, Wang F: Prospective study of herpes simplex virus, cytomegalovirus and the risk of future myocardial infarction and stroke. Circulation 1998; 98: 2796-2799.
35. Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Cornell JM: Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Colch) 2000; 98: 531-535.
36. Pitsavos C, Chrysohoou C, Panagiotakos DB, et al: Association of leisure-time physical activity on inflammation markers (C-reactive protein, white cell blood count, serum amyloid A and fibrinogen) in healthy subjects (from the ATTICA study). Am J Cardiol 2003; 91: 368-370.
37. Fuentes F, Lopez-Miranda J, Sanchez E, et al: Mediterranean and low-fat diets improve endothelial function in hypercholesterolemic men. Ann Intern Med 2001; 134:1115-1119.
38. Cooke JP: The endothelium: a new target for therapy. Vasc Med 2000; 5: 49-53.
39. Robertson RS, Tangney C, Casey LC: Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999; 353:119.
40. Jialal I, Stein D, Balis D, et al: Effect of hydroxymethyl glytaryl coenzyme A reductase inhibitor therapy on high sensitivity C-reactive protein levels. Circulation 2001; 103: 1933.
41. Hatada EN, Krappmann D, Scheidereit C: NF-kB and the innate immune response. Curr Opin Immunol 2000; 12: 52-58.
42. Bhat D, Topol E: Need to test the arterial inflammation hypothesis. Circulation 2002; 106: 136-140.
43. Behrendt D, Ganz P: Endothelial function: From vascular biology to clinical applications. Am J Cardiol 2001; 90 (suppl): 40L-48L
44. Ikonomidis I, Andreotti F, Economou E, et al: Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999; 100: 793-798.
45. Coletta AP, Cleland JG: Clinical trials update: Highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology-WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur J Heart Fail 2001; 3: 747-750.
46. Hermann A, Rauch BH, Braun M, et al: Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression and inhibition by clopidogrel. Platelets 2001; 12: 74-82.
47. Santa-Cruz RA, Steinhubl SR: Clopidogrel: How good is it and how does it work? Curr Cardiol Rep 2004; 6: 264-268.
48. Burleigh ME, Bahaev VR, Dates JA, et al: Cycloxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 2002; 105: 1816-1823.
49. Konstam MA, Weir MR, Reicin A, et al: Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104: 2280-2288.
50. De Caterina R, Liao JK, Libby P: Fatty acid modulation of endothelial activation. Am J Clin Nutr 2000; 71(suppl): 213s-223s.
51. Lagrand W, Visser C, Hermens W, et al: C-reactive protein as a cardiovascular risk factor. More than an epiphenomenon? Circulation 1999; 100: 96-102.
52. Hubbard AK, Rothlein R: Intercellular adhesion molecule-1 (1CAM-1) expression and cell signalling cascades. Free Radic Biol Med 2000; 28: 1379-1386.
53. Ballou SP, Lozanski G: Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992; 4: 361-368.
54. Barnes PJ, Kavin M: Mechanisms of disease: nuclear factor-kB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1041-1045.